Urapidil (hydrochloride)

Urapidil (hydrochloride)

• CAS Number: 64887-14-5
• UNSPSC Description: Urapidil hydrochloride is an orally active α1-adrenoceptor antagonist and 5-HT1A receptor agonist with a pIC50 of 6.13 and 4.38 against α1- and α2-adrenoceptor, respectively. Urapidil hydrochloride shows antihypertensive effect[1][2].
• Target Antigen: 5-HT Receptor; Adrenergic Receptor
• Type: Reference compound
• Related Pathways: GPCR/G Protein;Neuronal Signaling
• Applications: COVID-19-immunoregulation
• Field of Research: Cardiovascular Disease; Endocrinology
• Assay Protocol: https://www.medchemexpress.com/urapidil-hydrochloride.html
• Purity: 99.97
• Solubility: DMSO : 14.29 mg/mL (ultrasonic;warming;heat to 60°C)|H2O : 100 mg/mL (ultrasonic)
• Smiles: O=C1N(C)C(C=C(NCCCN2CCN(C3=CC=CC=C3OC)CC2)N1C)=O.Cl
• Molecular Weight: 423.94
• References & Citations: [1]Gross, G., G. Hanft, and N. Kolassa, Urapidil and some analogues with hypotensive properties show high affinities for 5-hydroxytryptamine (5-HT) binding sites of the 5-HT1A subtype and for alpha 1-adrenoceptor binding sites. Naunyn Schmiedebergs Arch Pharmacol, 1987. 336(6): p. 597-601.|[2]Buch, J., Urapidil, a dual-acting antihypertensive agent: Current usage considerations. Adv Ther, 2010. 27(7): p. 426-43.|[3]Vanhaesebrouck S, et al. Neonatal transient respiratory depression after maternal urapidil infusion for hypertension. Eur J Pediatr. 2009 Feb;168(2):221-3.
• Shipping Conditions: Room Temperature
• Storage Conditions: 4°C (Powder, sealed storage, away from moisture)
• Clinical Information: Launched